Non-small-cell lung cancer (NSCLC) is a leading cause of cancer mortality[@b1]. Although chemotherapy remains the mainstream treatment of advanced NSCLC, small molecular tyrosine kinase inhibitors (TKIs) targeting specific driver mutations have resulted in favorable response rate, progression-free survival (PFS), and quality of life in sensitive population[@b2][@b3][@b4][@b5][@b6][@b7].

*Epidermal growth factor receptor (EGFR)* mutations are the first discovered druggable targets in NSCLC[@b8]. Two classes of *EGFR* mutations, exon 19 deletions and exon 21 substitutions, account for the majority of *EGFR* mutations reported (\~90%)[@b9]. These mutations are correlated with better response to gefitinib, erlotinib and afatinib[@b2][@b3][@b4]. And they were more frequently observed in Asian population, never smokers, females, and patients with adenocarcinoma[@b10]. A reverse relationship between cumulative smoking pack-years and the frequency of *EGFR* mutations has widely been reported[@b11][@b12], suggesting some predictive value of smoking status for the presence of *EGFR* mutations. However, the association between age at diagnosis and *EGFR* mutations remains controversial and little data is available regarding the predictive value of age at diagnosis on *EGFR* mutations[@b10][@b13][@b14][@b15].

Fusion of the *Echinoderm microtubule-associated protein like-4* (*EML4*) and *anaplastic lymphoma kinase* (*ALK*) represents another distinct mechanism of driver mutation in NSCLC. The fusion protein is highly oncogenic both in vitro and vivo, resulting in constitutive ALK pathway activation and ultimately cancer development[@b16][@b17]. Several clinical trials have demonstrated the remarkable efficacy of crizotinib for the treatment of metastatic NSCLC patients who harbor ALK rearrangements, which led to its approval from the US Food and Drug Administration and the European Medicines Agency[@b6][@b18][@b19]. *EML4-ALK* rearrangements were mostly reported to be associated with younger age at diagnosis and adenocarcinoma[@b20][@b21][@b22]. However, inconsistent reports still exist[@b6][@b22][@b23]. Also, the accuracy of age at diagnosis and smoking status in predicting *EML4-ALK* rearrangements has not been established.

One of the most challenging problems in clinical practice is to acquire adequate tumor tissue for genomic analysis. Therefore, using available clinicopathological data to predict the likelihood of certain genetic aberrations is of special significance. Furthermore, *EML4-ALK* rearrangements and *EGFR* mutations represent two distinct oncogenic mechanisms, which might have different clinicopathological features. However, a limited number of studies have concerned about such difference in a single dataset.

We therefore carried out this epidemiological study based on large-scale genotyped NSCLC patients to evaluate the distinct clinicopathological features associated with *ALK* rearrangements and *EGFR* mutations in Chinese Han population, as well as the predictive value of age at diagnosis and smoking pack-years on these two genetic aberrations.

Results
=======

Population characteristics
--------------------------

From 10^th^ January 2012 to 25^th^ April 2014, 1377 NSCLC patients were prospectively enrolled in Sun Yat-sen University Cancer Center. After excluding 102 patients who had insufficient tumor tissue for genomic analysis and another 115 patients who refused to participate in the study, a total of 1160 patients were finally included. [Figure 1](#f1){ref-type="fig"} outlines the process of patient selection. Overall clinicopathological features of the included patients are summarized in [Table 1](#t1){ref-type="table"}. The median age at diagnosis was 57 years (range: 19--85 years). Among them, 39.1% were females, 54.0% were never-smokers, 78.1% had adenocarcinoma, and 43.0% were diagnosed at stage IIIB-IV. Females were more likely to be non-smokers (*p* \< 0.001). The incidence of *EML4-ALK* rearrangements and *EGFR* mutations was 8.1% (*n* = 94) and 33.8% (*n* = 392), respectively. Two cases of concurrent ALK rearrangement and EGFR mutation were noted, whose clinical and pathological data are presented in [Supplementary Table S1](#s1){ref-type="supplementary-material"} online.

Association between clinicopathological data and *EML4-ALK* rearrangements
--------------------------------------------------------------------------

Patients with *EML4-ALK* rearrangements were significantly younger at diagnosis than those without such rearrangements (median age, 45 versus 58 years; *p* \< 0.001). Never smokers were more likely to harbor *EML4-ALK* rearrangements than smokers (10.1% versus 6.1%; *p* = 0.005). Patients with advanced NSCLC (stage IIIB-IV) had significantly higher incidence of *EML4-ALK* rearrangements compared with those diagnosed at stage I-IIIA (10.6% versus 6.2%; *p* = 0.006). 8.9% of adenocarcinoma and 4.7% of non-adenocarcinoma had *EML4-ALK* rearrangements, respectively (*p* = 0.036). For symptoms at first onset, none of the symptoms were found to be significantly associated with *EGFR* mutations or *ALK* rearrangements. The results of univariate logistic analysis are shown in [Table 1](#t1){ref-type="table"}.

In order to adjust for confounding factors, we carried out multivariate logistic regression analysis. The results showed that only younger age at diagnosis remained independently associated with *EML4-AL*K rearrangements (odds ratio (OR) per 5 years\' increment, 0.68; 95% confidence interval (CI), 0.62--0.75; *p* \< 0.001). The remaining variables, including smoking status (*p* = 0.223), cancer stage (*p* = 0.500), and pathological types (*p* = 0.051) were no longer associated with *EML4-ALK* rearrangements.

Association between clinicopathological data and *EGFR* mutations
-----------------------------------------------------------------

The results of univariate analysis are shown in [Table 1](#t1){ref-type="table"}. Female patients were more likely to have *EGFR* mutations compared with male patients (46.7% versus 25.5%; *p* \< 0.001). Never smokers had higher incidence of *EGFR* mutations than smokers did (45.9% versus 21.1%; *p* \< 0.001). Adenocarcinoma (*p* \< 0.001) and moderate to high differentiation (*p* \< 0.001) were also significantly associated with *EGFR* mutations. Subsequent multivariate logistic regression analysis showed that lower tobacco exposure (OR per 5 pack-years\' increment, 0.88; 95% CI, 0.85--0.92; *p* \< 0.001), adenocarcinoma (OR, 6.61; 95% CI, 3.58--12.19; *p* \< 0.001), and moderate to high differentiation (OR, 2.05; 95% CI, 1.55--2.71; *p* \< 0.001) were independent predictors of harboring *EGFR* mutations. However, gender (*p* = 0.154) and cancer stage (*p* = 0.767) were not considered to be independently associated anymore.

Age at diagnosis as a predictor of *EML4-ALK* rearrangements and *EGFR* mutations
---------------------------------------------------------------------------------

We sought to investigate the impacts of age at diagnosis (denoted as "age" in the following contents) on the incidence of *EML4-ALK* rearrangements in detail, compared with those on *EGFR* mutations. The incidence of *EML4-ALK* rearrangements decreased dramatically with increasing age, while the incidence of *EGFR* mutations increased with age till 50--59 years and remained nearly unchanged with age ([Figure 2](#f2){ref-type="fig"}). Patients under the age of 30 had a 44% (7/16) incidence of *EML4-ALK* rearrangements, compared with a 4% (5/135) incidence in those above 70 years (*p* \< 0.001). Notably, when stratified by gender or smoking status, similar age-distribution patterns were also observed ([Figure 3](#f3){ref-type="fig"}).

To seek for cut-off value of age as a predictor of *EML4-ALK* rearrangements, ROC curve was plotted. The area under ROC curve (AUC) was 0.74 (95% CI, 0.68--0.80) with the cut-off age of 50.5 years (sensitivity, 73%; specificity, 70%) ([Figure 4A](#f4){ref-type="fig"}). Patients under 50.5 years old had an 18.5% (66/356) incidence of *EML4-ALK* rearrangements compared with a 3.5% (28/804) incidence in patients above 50.5 years old (OR = 6.1; *p* \< 0.001). This cut-off value also showed fair discriminative power in patients with different clinicopathological features ([Table 2](#t2){ref-type="table"}). In patients younger than 50.5 years old, when we added "*EGFR* wild type" and "adenocarcinoma" into the enrichment strategy, we got a 29.4% (58/197) incidence of *EML4-ALK* rearrangements.

We also plotted ROC curve for age as a predictor of *EGFR* mutations ([Figure 4B](#f4){ref-type="fig"}). The AUC was only 0.52 (95% CI, 0.49--0.56).

Smoking pack-years before diagnosis as a predictor of *EML4-ALK* rearrangements and *EGFR* mutations
----------------------------------------------------------------------------------------------------

The incidence of *EML4-ALK* rearrangements and *EGFR* mutations by smoking pack-years was shown in [Figure 5](#f5){ref-type="fig"}. Briefly, the incidence of *EGFR* mutations decreased with increasing smoking pack-years. A 5 pack-years\' increment led to a 12% decrease in the likelihood of *EGFR* mutations. However, there was a plateau of the incidence of *EGFR* mutations after more than 10 pack-years of cigarettes were consumed. Even in patients with more than 80 smoking pack-years, the incidence of *EGFR* mutations was as high as 13.2% (5/38). As for *EML4-ALK* rearrangements, the incidence peaked at 0--10 pack-years (20%) and then dropped with increasing cigarettes smoking.

The AUC for smoking pack-years as a predictor of *EML4-ALK* was 0.60 (95% CI, 0.55--0.65) with the optimal cut-off value of 10.25 pack-years (sensitivity, 41%; specificity, 82%) ([Figure 6A](#f6){ref-type="fig"}). Patients who smoked less than 10.25 pack-years were more likely to harbored *EML4-ALK* compared to those who smoked more than 10.25 pack-years (11.1% versus 3.8%; *p* \< 0.001). For *EGFR* mutations, the AUC was 0.66 (95% CI, 0.63--0.70) with the cut-off value of 2.75 pack-years (sensitivity, 55%; specificity 77%) ([Figure 6B](#f6){ref-type="fig"}). Patients who smoked less than 2.75 smoking pack-years had a 45.9% (291/634) incidence of *EGFR* mutations compared with a 17.4% (87/500) incidence in those who smoked more than 2.75 pack-years (OR, 4.0; 95% CI, 3.0--5.3; *p* \< 0.001).

Discussion
==========

In clinical practice, the discrimination of *ALK* rearrangements and *EGFR* mutations in NSCLC has critical therapeutic implications. *EGFR* mutations confer sensitivity to EGFR TKIs while patients with *ALK* rearrangements response well to ALK TKIs. However, *ALK* rearrangements are associated with resistance to EGFR TKIs[@b21][@b24]. Due to some shared features of *EML4-ALK* rearrangements and *EGFR* mutations such as adenocarcinoma histology and never/light smokers, it is important to investigate other distinct features of these two genetic aberrations. To our knowledge, this is the first study to investigate the roles of patients\' clinicopathological features in predicting the presence of *EML4-ALK* rearrangements and *EGFR* mutations.

We found age at diagnosis was the only variable that independently predicted *EML4-ALK* rearrangements. There was an inverse relationship between age at diagnosis and the frequency of *EML4-ALK* rearrangements. A 5-year\'s increment in age decreased the likelihood of *EML4-ALK* rearrangements by 32%. Using ROC curve, the cut-off age at diagnosis for predicting *EML4-ALK* rearrangements was determined to be 50.5 with a sensitivity of 73% and a specificity of 70%. Patients younger than 50.5 years had a five-fold greater chance of harboring *EML4-ALK* rearrangements compared with those older than 50.5 years. Noteworthy, this cut-off value also shows fair discriminative power in patients with various clinicopathological features ([Table 2](#t2){ref-type="table"}). For male and female patients, the ORs of ALK rearrangement in patients younger than 50.5 years versus those older than 50.5 years were similar (OR = 6.1 and 6.8, respectively). This implies that gender difference in ALK rearrangement might be limited. However, in non-smokers, the discriminative power seems lower (OR = 2.6). One possible explanation is that smoking status, though not as remarkable as age at diagnosis, still affects the incidence of ALK rearrangement. For histological subtypes (adenocarcinoma versus non-adenocarcinoma) and cancer stage (I-IIIA versus IIIB-IV), age at diagnosis also satisfactorily predict the likelihood of ALK rearrangement. Taken together, these results indicate age at diagnosis alone is a very strong predictor of *ALK* rearrangements in NSCLC. However, attention should be paid to non-smokers older than 50.5 years old who still have 7.6% incidence of ALK rearrangement. In an enriched population (younger than 50.5 years old, *EGFR* wild type and with adenocarcinoma histology), we found one-third of patients harbored *EML4-ALK* rearrangements. This enrichment strategy is useful when assessing the likelihood of *EML4-ALK* rearrangements in NSCLC patients. Our results have several conflicts with a prospective *ALK* screening study, which showed that male patients, light/never smokers and N3 stage were independently associated with *ALK* rearrangements[@b22]. The discrepancy, which remains to be elucidated, is probably due to the small sample size in the previous study (only 16 positive cases from 116 patients), the obvious selection bias reported, or simply the ethnic difference.

Our results also revealed that the predictive power of smoking pack-years on *EML4-ALK* rearrangements was limited. This is unsurprising since smoking status was not an independent variable associated with *EML4-ALK* rearrangements. Indeed, they have been sporadically reported in both smokers and nonsmokers[@b22][@b25][@b26], indicating a lack of association between smoking status and *EML4-ALK* rearrangements.

As for *EGFR* mutations, we found that lower tobacco exposure, adenocarcinoma, and moderate to high differentiation were independently associated with *EGFR* mutations. Similar to a prospective *EGFR* screening study in Asian[@b10], we found female was associated with *EGFR* mutations in univariate analysis but not in multivariate logistic regression model, suggesting internal association between gender and other variables such as smoking status. Until now, it is widely believed that female rather than male patients should be tested for *EGFR* mutations. This unspoken prejudice may miss out a substantial of patients who will benefit from targeted therapy. A previous study which established a nomogram to predict the presence of *EGFR* mutations also indicated that gender has little contribution to such prediction while smoking pack-years is the strongest predictor[@b27].

The association between age at diagnosis and *EGFR* mutations has long been controversial. Some studies showed that patients with *EGFR* mutations were older than those without *EGFR* mutations[@b13][@b14][@b15], While other studies found no significant association[@b10][@b28]. In the present study, we found age at diagnosis was not associated with *EGFR* mutations, which was further supported by ROC curve (AUC = 0.52). These results suggest that the likelihood of *EGFR* mutations is poorly predicted by age at diagnosis. One possible explanation might be that there is a peak incidence of *EGFR* mutations around 60 years old ([Figure 1](#f1){ref-type="fig"}, "n" shape distribution). This was also supported by the nomogram model from Girard et al\'s study which shows that patients aged between 60 and 70 have higher probability of *EGFR* mutations[@b27].

Finally, we explored the roles of smoking pack-years in predicting *EGFR* mutations. We found the incidence of *EGFR* mutations was inversely related to smoking pack-years, similar to a previous study[@b11]. In that study, they concluded that smoking pack-years strongly predicted *EGFR* mutations (AUC = 0.78). No patients that have smoked more than 75 pack-years harbor *EGFR* mutations. In the current study, however, the AUC was lower (AUC = 0.66). Indeed, we observed a plateau of the incidence of *EGFR* mutations after more than 10 pack-years of cigarettes consumption, suggesting that smoking has no cumulative effects on *EGFR* mutations. Patients who have smoked more than 80 pack-years still had a 13.2% incidence of *EGFR* mutations. Therefore heavier smokers should still be considered for *EGFR* mutation tests[@b29]. This finding also explains why the predictive accuracy of smoking pack-years reported here was lower than previously believed[@b11].

The distinct age-distribution patterns of *EML4-ALK* rearrangements and *EGFR* mutations may also imply the difference of oncogenic potency. NSCLCs with *EGFR* mutations are generally dormant and would take a longer time to become clinically detectable, resulting in accumulated occurrence of *EGFR* mutant tumors in patients of relatively older age. While chromosomal abnormalities may result in structural changes of critical proteins and hence more aggressive tumors which require less time to become overt diseases. In favor of this point, other cancer types including anaplastic large cell lymphomas, inflammatory myofibroblastic tumor, and neuroblastoma that harbor *ALK* rearrangements occur predominantly in children and young adults. Other fusion genes in NSCLC, such as *ROS1* and *RET* are also associated with younger age at diagnosis[@b30][@b31], suggesting a class-specific characteristic of fusion genes that differ from point mutations or indels (insertions and deletions) such as Kras mutations and PI3CA mutations[@b32][@b33]. Therefore, in very young NSCLC patients, the tests of *ALK* rearrangements should be given priority over *EGFR* mutations (especially in those younger than 30 years old). Furthermore, in vitro and in vivo studies to investigate the biological difference between these two oncogenic mechanisms are warranted.

Due to the remarkable clinical benefits of tyrosine-kinase inhibitors in NSCLC patients who harbor corresponding driver mutations, pretreatment multiplex genetic tests should be performed to guide therapeutic decisions. However, when tumor tissue is scarce, we may use clinicopathological features to predict specific genetic aberrations. Our study for the first time demonstrates that age at diagnosis alone can be a valuable tool to predict the presence of *EML4-ALK* rearrangement with fair sensitivity and specificity. While smoking pack-years but not age at diagnosis may predict *EGFR* mutations, as supported by previous and current study. However, the predictive power of smoking-pack-years reported here is less evident and we suggest not omitting heavier smokers from *EGFR* mutation testing in East Asian population.

Our study have several limitations. First, this is a single-institution study. However, we prospectively enrolled consecutive NSCLC patients seen in our hospital. We believe these unselected patients are fair representative of NSCLC patients across different pathological types. Second, we did not carry out survival analysis due to immature survival data. It would be interesting to evaluate the prognostic value of clinicopathological variables and mutation types. A recent study by Li C et al. shows that no survival difference was noted in lung adenocarcinoma according to different driver mutations[@b34]. Yet, some studies found that ALK+ was associated with worse disease-free survival in NSCLC[@b35][@b36]. Overall, the prognostic value of different driver mutations are controversial which is probably due to more complicated treatment options in the era of targeted therapy. Third, we only focused on two currently druggable targets in NSCLC. Other driver mutations including KRAS, BRAF, HER2, MET, PTEN, RET, etc. have also been reported in previous studies[@b35]. Whether these driver share similar phenomenon needs further investigation.

In summary, we show that age at diagnosis alone is a valuable predictor of *EML4-ALK* rearrangements but poorly predicts *EGFR* mutations in NSCLC. Smoking pack-years may predict *EGFR* mutations though with limited power. We recommend the detection of *EGFR* mutations should not be confined to patients with "advantageous" features like younger patients, females and non-smoking. The results should help assess the likelihood of these two genetic aberrations based on available clinicopathological features and understand the biological implications of different driver mutations.

Methods
=======

Patients and sample collection
------------------------------

This cross-sectional study was to determine the overall incidence of *EML4-ALK* rearrangement and *EGFR* mutation in Chinese Han population diagnosed as NSCLC; to investigate the distinct clinicopathological pathological features of patients who harbored *EML4-ALK* rearrangements or *EGFR* mutations; and to evaluate the predictive value of age at diagnosis and smoking pack-years years for these two genetic aberrations. Patients who met the following criteria were prospectively enrolled: histologically or cytologically proven NSCLC patients by two independent pathologists (Y. Li and J.T. Jin); aged 18 years or older; able to provide informed consent; available and sufficient tumor tissue (biopsy or surgical specimen) for genomic analysis. Specimens were obtained from two sources: fresh-frozen tumor samples from the Biobank of SYSUCC and formalin-fixed, paraffin-embedded (FFPE) tissue submitted to the Department of Pathology (within 5 years before enrollment). The study was conducted in accordance with the Declaration of Helsinki, International Conference on Harmonisation Guidelines for Good Clinical Practice and was approved by the Ethics Committee of SYSUCC. Informed consent was obtained for each participant before the acquisition of tumor tissue.

Genetic analysis
----------------

*EGFR* mutations were detected using PCR-based direct sequencing of exons 18--21 as previously described[@b31]. Briefly, genomic DNA was extracted from either tumors embedded in paraffin blocks or from fresh frozen tumors. PCR amplification was done using HotStarTaq DNA polymerase (Qiagen Inc., Valencia, CA) with a forward primer (5′-GGATCGGCCTCTTCATGC3′) and a reverse primer (5′-TAAAATTGATTCCAATGCCATCC-3′). PCR products were sequenced directly using Applied Biosystems PRISM dye terminator cycle sequencing method (Perkin-Elmer Corp., Foster City, CA) with ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA). Any in-frame deletions in exon 19 or point mutations in exon 21 (L858R or L861Q substitutions), which confer sensitivity to EGFR-TKIs therapy, were considered as *EGFR* mutant. *EML4-ALK* rearrangements were detected by means of Fluorescence in situ Hybridization (FISH) using a break-apart probe to the ALK gene (Vysis LSI ALK Dual Color, Break Apart Rearrangement Probe; Abbott Molecular) per manufacturer\'s instructions. At least 100 representative tumor cells were counted. The results obtained by FISH were analyzed using an Olympus fluorescence microscope equipped with orange, green, and 4′, 6-diamidino-2-phenylindole filters. Images were captured using the Video Test Image Analysis System. FISH-positive cases were defined as ≥15% of the tumor cells that showed a split red and green signal and/or an isolated (single) red signal. Otherwise, the specimen was classified as ALK FISH negative.

Clinicopathological data
------------------------

Clinicopathological features including age at diagnosis, gender, smoking history, pathological types, differentiation, cancer stage, symptoms at first onset and family history of malignant tumors were carefully collected. Lung cancer was histologically classified as adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma and other subtypes. Cancer stage was determined according to TNM classification according to the Union for International Cancer Control and the American Joint Committee on Cancer staging system, 7th edition[@b32]. Smokers were defined as those who had more than 100 lifetime cigarettes. Smoking pack-years was calculated as average number of cigarettes per day/20× years smoking and was treated as a continuous variable.

Statistical analysis
--------------------

Chi-square test (or Fisher exact test) and independent-samples t-test were applied to explore the univariate association between clinicopathological variables and specific genetic aberrations, for categorical and continuous data, respectively. All variables that were univariately associated at the level of *α* \< 0.2 were included in the multivariate logistic regression model. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to denote the association. The receiver operating characteristic (ROC) curve methodology was applied to assess the ability of age at diagnosis or smoking pack-years to predict *EML4-ALK* rearrangements and *EGFR* mutations. The diagnostic accuracy was presented as the area under the ROC curve (AUC). All statistical calculations were performed using SPSS version 21.0 (SPSS, Inc., Chicago, IL.) A two-tail *P* value of \< 0.05 was judged significant.
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###### Demographic and clinicopathological characteristics of non-small-cell lung cancer patients with defined *EML4-ALK* rearrangement and *EGFR* mutation status

                                                  *EML4-ALK* rearrangement     *EGFR* mutation                                                            
  ------------------------------- ------------ ---------------------------- ------------------- --------------------------------------- -------- -------- -----------------------------------------
  Patients, *n*                       1160                  94                     1066                                                   392      768                         
  Age at diagnosis, years                                                                                                                                                      
  Median                               57                   45                      58                        **\<0.001**                  57       57                      0.597
  Range                              19--85               20--81                  19--85                                                 27--81   19--85                       
  Gender, *n*                                                                                                                                                                  
  Female                           454 (39.1)               40                      414                          0.479                    212      242                   **\<0.001**
  Male                             706 (60.9)               54                      652                                                   180      526                         
  Smoking status, *n*                                                                                                                                                          
  Never smoking                    626 (54.0)               64                      562          **0.005**[\*](#t1-fn1){ref-type="fn"}    272      320     **\<0.001**[\*](#t1-fn1){ref-type="fn"}
  Smoking                          525 (45.3)               30                      495                                                   118      441                         
  Unknown                           9 (0.8)                 0                        9                                                     2        7                          
  Pathology, *n*                                                                                                                                                               
  Adenocarcinoma                   906 (78.1)               81                      825          **0.036**[§](#t1-fn2){ref-type="fn"}     368      538     **\<0.001**[§](#t1-fn2){ref-type="fn"}
  Squamous                         168 (14.5)               9                       159                                                    12      156                         
  Adenosquamous                     22 (1.9)                2                       20                                                     9        13                         
  Others                            64 (5.5)                2                       62                                                     3        61                         
  Differentiation, *n*                                                                                                                                                         
  Moderate to high                 434 (37.4)               31                      403            0.649[£](#t1-fn3){ref-type="fn"}       200      234     **\<0.001**[£](#t1-fn3){ref-type="fn"}
  Poor                             632 (54.5)               55                      577                                                   161      471                         
  Undetermined                      94 (8.1)                8                       86                                                     31       33                         
  Stage, *n*                                                                                                                                                                   
  I--IIIA                          661 (57.0)               41                      620                        **0.007**                  212      449                      0.154
  IIIB--IV                         499 (43.0)               53                      446                                                   180      319                         
  Family history of cancer, *n*                                                                                                                                                
  Yes                              238 (20.5)               22                      216                          0.470                     79      159                      0.826
  No                               922 (79.5)               72                      850                                                   313      609                         
  Cough, n                                                                                                                                                                     
  Yes                              856 (73.8)               68                      788                          0.738                    300      488                      0.139
  No                               304 (26.2)               26                      278                                                    92      186                         
  Chest pain, n                                                                                                                                                                
  Yes                              504 (43.4)               39                      465                          0.690                    181      323                      0.181
  No                               656 (56.6)               55                      601                                                   211      445                         
  Hemoptysis, n                                                                                                                                                                
  Yes                              258 (22.2)               14                      244                          0.077                     93      165                      0.867
  No                               902 (77.8)               80                      822                                                   299      603                         
  Shortness of breath, n                                                                                                                                                       
  Yes                                 336                   20                      316                          0.089                    121      215                      0.308
  No                                  824                   74                      750                                                   271      553                         

\*p values compare never smoking with smoking.

^§^p values compare adenocarcinoma plus adenosquamous with squamous and others.

^£^p values compare moderate to high differentiation with poor differentiation.

Bold fonts indicate significant p values.

###### Odds ratio of *EML4-ALK* rearrangements in patients younger than 50.5 yrs versus patients older than 50.5 yrs, stratified by clinicopathological features

                                                 \<50.5 years old     \>50.5 years old                                   
  ------------------------------------------- -------------------- -------------------- -------- ----- ----- ----------- ---------
  Gender                                                                                                                      
  Male                                               35/186                18.8          19/520   3.7   6.1   3.4--11.0   \<0.001
  Female                                             31/170                18.2          9/284    3.2   6.8   3.2--14.7   \<0.001
  Smoking status                                                                                                              
  Smoking                                            21/123                17.1          9/402    2.2   9.0   4.0--20.2   \<0.001
  Non-smoking                                        29/165                17.6          35/461   7.6   2.6   1.5--4.4    \<0.001
  Histological subtypes                                                                                                       
  Adenocarcinoma[§](#t2-fn1){ref-type="fn"}          60/300                20.0          23/628   3.7   6.6   4.0--10.9   \<0.001
  Non-adenocarcinoma                                  6/57                 10.5          5/175    2.9   4.0   1.2--13.6    0.027
  Cancer stage                                                                                                                
  I--IIIA                                            24/148                16.2          17/513   3.3   5.2   2.9--10.8   \<0.001
  IIIB--IV                                           42/208                20.2          11/291   3.8   6.4   3.2--12.9   \<0.001

^§^Adenocarcinoma includes adenocarcinoma and adenosquamous carcinoma.

Abbreviations: OR, odds ratio; CI, confidence interval. Yrs, years old.
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